Antibody response of pediatric solid organ transplant recipients to immunization against influenza virus

Mauch, Teri Jo; Crouch, Norman A.; Freese, Deborah K.; Braunlin, Elizabeth; Dünn, David L.; Kashtan, Clifford E.

doi:10.1016/s0022-3476(95)70037-4

Cited by 59 publications

(37 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…73 Pediatric patients after both renal and liver transplantation appear to be adequately protected by influenza vaccination. 63,74 The percentage of pediatric liver transplant recipients with protective antibody titer after 1 month from the vaccination was 67% in 1 study. 62 Older age and lower doses of corticosteroids were associated with better responses.…”

Section: Vaccinationmentioning

confidence: 92%

Influenza Infection in Patients Before and After Liver Transplantation

Duchini¹

2000

Liver Transplantation

View full text Add to dashboard Cite

Infection with influenza virus poses specific problems in pediatric and adult liver transplant recipients, both before and after liver transplantation. These include a higher rate of pulmonary and extrapulmonary complications, development of rejection with graft dysfunction, prolonged shedding of influenza virus, and increased drug-resistance. Hepatic decompensation may occur during influenza infection in patients with cirrhosis. Current prophylaxis includes yearly vaccination with trivalent inactivated vaccine. Appropriate diagnosis and prompt treatment of any upper respiratory infections are indicated in these patients. In this review, we describe a case of influenza viral pneumonia in an adult liver transplant recipient, review basic and clinical aspects of influenza infection in this patient population, and discuss current modes of prevention and treatment in detail. (Liver Transpl 2000;6: 531-542.)

show abstract

Section: Vaccinationmentioning

confidence: 92%

Influenza Infection in Patients Before and After Liver Transplantation

Duchini¹

2000

Liver Transplantation

View full text Add to dashboard Cite

show abstract

“…In studies of the humoral response in transplant populations, the use of mycophenolate mofetil [17] or cyclosporine [18,19] and decreased allograft function [11,19,20] were all predictors of decreased antibody response in some, but not other studies. Prior immunization and younger age were predictors of increased antibody response [10,21]. In studies that used booster doses, these were not found to increase antibody production [3,10,13,19,21].…”

mentioning

confidence: 87%

“…Prior immunization and younger age were predictors of increased antibody response [10,21]. In studies that used booster doses, these were not found to increase antibody production [3,10,13,19,21].…”

mentioning

confidence: 87%

“…¢1:40) or who develop a serological response (i.e. ¢four-fold increase in titre) [9][10][11][12]. Nonmedication related factors have been identified that may alter the humoral response to the vaccine in a normal host.…”

mentioning

confidence: 99%

“…In particular, it tends to be more immunogenic in individuals who have had prior antigenic experience (i.e. infection, prior immunization) [10][11][12][13] and less immunogenic in the elderly [14], those with endstage renal disease, and those with advanced human immunodeficiency virus (HIV) infection [9,10,13,15,16]. In studies of the humoral response in transplant populations, the use of mycophenolate mofetil [17] or cyclosporine [18,19] and decreased allograft function [11,19,20] were all predictors of decreased antibody response in some, but not other studies.…”

mentioning

confidence: 99%

See 2 more Smart Citations

The humoral immune response to influenza vaccination in lung transplant patients

et al. 2001

View full text Add to dashboard Cite

The purpose of this study was to evaluate the humoral immune response to influenza vaccination in lung transplant recipients.Antibody levels to the three viral antigens included in the 1999-2000 trivalent influenza vaccine (A/Sydney/5/97-like (H3N2), A/Beijing262/95-like (H1N1), and B/Yamanashi/16/ 98) were measured before and 4 weeks postvaccination in 43 lung transplant recipients and 21 healthy adult controls. The ability to develop protective antibody levels, a serological response, and the magnitude of change in levels were assessed.The humoral immune response to influenza vaccination was significantly lower in the transplant group for all three viral antigens. To A/Sydney, 95% of the control group and 40% of the transplant group developed protective levels (p=0.0009); to A/Beijing, 71% of the control group and 30% of the transplant group developed protective levels (p=0.004); and to B/Yamanashi, 48% of the control group and 19% of the transplant group developed protective levels (p=0.02). Those receiving cyclosporine had lower antibody responses when compared to those receiving tacrolimus (r=-0.3056, p=0.0463).The humoral immune response to influenza vaccination in lung transplant recipients is poor. Lung transplant recipients receiving cyclosporine may have a lower antibody response than those receiving tacrolimus. Alternative prevention strategies may be needed. Eur Respir J 2001; 18: 971-976.

show abstract